Compare SPRY & TRTX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | SPRY | TRTX |
|---|---|---|
| Founded | 2015 | 2014 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Real Estate Investment Trusts |
| Sector | Health Care | Real Estate |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 634.5M | 660.2M |
| IPO Year | 2020 | 2015 |
| Metric | SPRY | TRTX |
|---|---|---|
| Price | $5.90 | $7.76 |
| Analyst Decision | Strong Buy | Buy |
| Analyst Count | 1 | 4 |
| Target Price | ★ $40.00 | $9.83 |
| AVG Volume (30 Days) | ★ 1.7M | 861.5K |
| Earning Date | 05-11-2026 | 04-28-2026 |
| Dividend Yield | N/A | ★ 11.55% |
| EPS Growth | N/A | ★ N/A |
| EPS | N/A | ★ 0.19 |
| Revenue | ★ $84,278,000.00 | N/A |
| Revenue This Year | $87.40 | $8.78 |
| Revenue Next Year | $81.64 | $4.14 |
| P/E Ratio | ★ N/A | $40.74 |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $4.91 | $7.57 |
| 52 Week High | $13.15 | $9.85 |
| Indicator | SPRY | TRTX |
|---|---|---|
| Relative Strength Index (RSI) | 47.54 | 37.48 |
| Support Level | $4.96 | $7.57 |
| Resistance Level | $6.58 | $8.74 |
| Average True Range (ATR) | 0.38 | 0.13 |
| MACD | 0.09 | -0.00 |
| Stochastic Oscillator | 61.08 | 25.00 |
ARS Pharmaceuticals Inc is a biopharmaceutical company focused on the commercialization and development of neffy (currently identified in the European Union (EU) and United Kingdom (U.K.) by the trade name EURneffy and in China) for needle-free intranasal delivery of epinephrine for emergency treatment of Type I allergic reactions, including anaphylaxis. Neffy is a proprietary composition of epinephrine with an absorption enhancer called Intravail, which allows Neffy to safely provide intranasal delivery of epinephrine at a low dose within the exposures of approved injectable products across a range of dosing conditions.
TPG RE Finance Trust Inc is a commercial real estate finance company. It originates, acquires, and manages commercial mortgage loans and other commercial real estate-related debt instruments consisting of first mortgage loans and senior participation interests in first mortgage loans secured by institutional-quality properties in primary and select secondary markets in the United States. The company's objective is to provide attractive risk-adjusted returns to its stockholders over time through cash distributions and capital appreciation. It focuses on directly originating and selectively acquiring floating-rate first mortgage loans that are secured by high-quality commercial real estate properties undergoing some form of transition and value creation.